Raising the Bar: A Higher Standard for Mental Health Care

This is the third edition of Forward Focus, a regular feature exploring the future of mental health with precision and purpose.

Psychiatry is at an inflection point.

Recently, Definium announced positive topline results from Emerge, our Phase 3 study investigating a pharmaceutically optimized formulation of LSD for major depressive disorder (MDD). Beyond marking an important milestone for our program, the results invite a broader conversation about what patients and physicians should expect from treatment—and whether the standards by which we have in the past measured success in psychiatry are ambitious enough.

For decades, psychiatric drug development has been characterized by incremental gains. In the process, we may have become too comfortable with outcomes that leave many patients still struggling with significant unresolved symptom burden.

Perhaps the most important question is this: Have we aimed high enough?

Patients don’t need another treatment that simply blunts symptoms. They deserve an intervention that has the potential to drive deeper, more meaningful response, to reshape how they navigate their days and think about their future.

The Emerge results suggest it may be time to rethink how high the bar should be for success in psychiatric medicine.

A Fundamental Reorientation

While remission has long been the aspiration of psychiatric care, it has too often remained elusive for some patients. We believe the field should continue striving toward treatments that make remission a goal.

Our investigational product candidate, DT120, is designed to do more than reduce symptoms. In our late-stage clinical trials, we are studying whether a single treatment experience can help patients achieve meaningful and durable improvement without the burden of taking a daily medication.

Driven by Collaboration and Courage

Progress of this magnitude is only possible because of the collective efforts of our dedicated community, willing to challenge conventional assumptions and advance the science together.

• To the clinical trial participants who have placed their trust in the trial: Your bravery is the foundation of our progress. Thank you.
• To the clinical investigators and site staff who worked tirelessly to make the Emerge trial possible: Thank you.
• And to the employees of Definium, none of this would be possible without your dedication, thoughtfulness and embrace of the boundless potential we are pursuing. Thank you.

This is Just the Beginning

The next era of psychiatry should be defined by a higher standard—one that aims to both reduce suffering and help people reclaim their lives.

If we are willing to raise our expectations for what treatment can achieve, I believe the future of mental health care is closer than ever.